The Share

The Diamyd Medical share is traded on Nasdaq First North (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North

Nasdaq First North is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399.

Annual Report

  November 9, 2017
  Quarterly Report 1, January 24, 2018

Dear Shareholders and readers

The last two months were dominated by new and promising results from DIAGNODE-1, the ongoing investigator-initiated trial where the diabetes vaccine Diamyd® is administered to the lymph node in recently diagnosed patients suffering from Type 1 diabetes. The treatment aims to interrupt the immune system’s attack on the insulin-producing cells and in this way preserve the remaining endogenous insulin production at the time of diagnosis. The value of such treatment is considerable for both patients and society, as...

The last two months were dominated by new and promising results from DIAGNODE-1, the ongoing investigator-initiated trial where the diabetes vaccine Diamyd® is administered to the lymph node in recently diagnosed patients suffering from Type 1 diabetes.
Ulf Hannelius, President and CEO

Calendar

 Dates for financial information and other events
March 8, 2018
Hållbarhetsturné med Feminvest och Nordnet
17:00 - 20:30 Norrtullsgatan 12 N, Stockholm
Register here
March 28, 2018
Quarterly Report II
Quarterly Report 2 2017/2018
June 27, 2018
Quarterly Report III
Quarterly Report 3 2017/2018
October 10, 2018
Financial statement
Financial statement 2017/2018
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of December 29, 2017

ShareholderA SharesB SharesCapital %Votes %
Essen-Möller, Anders 2 130 186 6 110 867 14.63 36.31
Avanza Pension 6 174 671 10.96 8.18
Lindkvist, Bertil 6 160 000 10.93 8.16
Nordnet Pensionsförsäkring AB 2 141 518 3.80 2.84
Hansen, Patrik 1 300 000 2.31 1.72
Swedbank Försäkring 896 114 1.59 1.19
Arandi Development AB 500 000 0.89 0.66
Ålandsbanken AB 475 321 0.84 0.63
Konstruktions o Försäljningsaktiebolag 404 666 0.72 0.54
Relbo AB 396 292 0.70 0.52
Remaining shareholders 29 644 269 52.62 39.26
Total 2 130 186 54 203 718 100.0 100.0